Medtronic (MDT) Stock
Leading global medical device maker for chronic conditions. Here's the price, business snapshot, and what's worth knowing about Medtronic in October 2026.
Medtronic PLC (MDT) is a leading global medical-technology company that designs, manufactures and sells a wide range of devices and therapies across cardiac, vascular, diabetes, neurological and spinal markets. Its portfolio includes pacemakers, insulin pumps, neurostimulation systems, spinal implants and surgical tools, generating a mix of implanted-device revenue and recurring consumables. With a market capitalisation of about $122.91bn, Medtronic benefits from ageing populations, steady demand for long-lived devices and an ongoing pipeline of incremental innovations. Important investor considerations include regulatory scrutiny, reimbursement and pricing pressures, competition from peers and emerging entrants, and occasional litigation. The company has historically returned cash through dividends and buybacks, but future payouts depend on cash flow and strategic priorities. This overview is general educational information only and not personalised investment advice; values can rise or fall and past performance is not a guarantee of future results.
Why It’s Moving
Medtronic bucks market dip as analysts highlight valuation discount and post-separation growth engines
- Stock gained 2.46% on October 29 while the wider market dipped, settling at $97.11 amid renewed focus on its trading at a 20.8% P/E discount to the sector median.
- Q1 FY2027 results showed ~7% organic revenue growth (adjusted for an extra week), driven by key growth engines like pulsed field ablation (PFA) in Cardiovascular and enabling technologies in Spine.
- Management is prioritizing the translation of this top-line growth into durable earnings leverage, noting that margin expansion remains limited despite the successful post-MiniMed separation strategy.
Medtronic bucks market dip as analysts highlight valuation discount and post-separation growth engines
- Stock gained 2.46% on October 29 while the wider market dipped, settling at $97.11 amid renewed focus on its trading at a 20.8% P/E discount to the sector median.
- Q1 FY2027 results showed ~7% organic revenue growth (adjusted for an extra week), driven by key growth engines like pulsed field ablation (PFA) in Cardiovascular and enabling technologies in Spine.
- Management is prioritizing the translation of this top-line growth into durable earnings leverage, noting that margin expansion remains limited despite the successful post-MiniMed separation strategy.
Sixth Month Growth Performance
When is the next earnings date for MEDTRONIC PLC (MDT)?
Medtronic has not yet announced a confirmed date for its next earnings release. Based on the company's historical reporting pattern, which typically occurs approximately three months after the previous quarter's close, the upcoming report is expected in early December 2026. This scheduled update will cover financial results for the fourth fiscal quarter of 2026. Investors should monitor official channels for the precise confirmation of this anticipated timing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Medtronic's stock with a target price of $98.14, indicating potential growth.
Financial Health
Medtronic is showing strong revenue and profit generation, supported by healthy cash flow metrics.
Dividend
Medtronic's dividend yield of 2.99% is considered average, providing steady income for shareholders. If you invested $1000 you would be paid $28.50 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Steady implant demand
Implanted devices and related consumables can provide recurring revenue as populations age, though demand and pricing may vary across markets.
Global market reach
Sales span developed and emerging markets, offering diversification but exposing the company to currency and local reimbursement risks.
R&D-driven pipeline
Ongoing product development and approvals can drive long-term growth, although clinical outcomes and commercial uptake are uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
